2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.Peer-Reviewed Original ResearchConceptsResectable pancreatic ductal adenocarcinomaCC-486OBS patientsMetastatic settingAdjuvant therapyTreatment-related grade 3Randomized phase II studyMedian age 66Next-line therapyResultsForty-nine patientsMedian treatment durationPhase II studyEvidence of diseaseHigh-risk featuresPhase II trialProgression-free survivalStandard adjuvant therapyPancreatic ductal adenocarcinomaCancer recursEvaluable patientsMedian OSMedian PFSOral azacitidineR1 resectionSubsequent chemotherapy
2020
S0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database
Ilagan-Ying Y, Ying L, Ferrucci L, Peters N, Blackburn H, Kunstman J, Ahuja N. S0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database. The American Journal Of Gastroenterology 2020, 115: s48-s49. DOI: 10.14309/01.ajg.0000702452.53969.ae.Peer-Reviewed Original ResearchAssociation of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2018
A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
Thakar M, Hu Y, Morreale M, Lerner L, Lin W, Sen R, Cai Y, Karunasena E, Thakar M, Saggi S, Keer H, Ahuja N. A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. PLOS ONE 2018, 13: e0199130. PMID: 29927979, PMCID: PMC6013229, DOI: 10.1371/journal.pone.0199130.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaDNA methyltransferase 1Chemotherapeutic agent irinotecanEpigenetic modulating agentsPDAC cell linesCell viabilityMechanism of actionSystemic chemotherapyCancer mortalityChemotherapy responseDuctal adenocarcinomaChemotherapy agentsEpigenetic sensitizationModulating agentsGuadecitabineAdditional studiesPancreatic cellsSerial concentrationsRest periodCell linesNanomolar concentrationsImproved responseEpigenetic modulatorsSensitizationMethyltransferase 1Epigenetic Pharmacology
Burkhart R, Sharma A, Ahuja N. Epigenetic Pharmacology. 2018, 1551-1575. DOI: 10.1007/978-1-4939-7193-0_69.Peer-Reviewed Original ResearchTranslation of genesHistone modificationsDNA methylationGenetic basisAssociated gene mutationsBiology of diseaseVariety of mechanismsTremendous discoveriesProtein expressionEpigeneticsGene mutationsDecades of researchPancreatic ductal adenocarcinomaEpigenomeMolecular agentsTranscriptionGenesMethylationBiologyMechanismMutationsDuctal adenocarcinomaPotential impactExpressionCurrent research efforts
2016
Epigenetic Pharmacology
Burkhart R, Sharma A, Ahuja N. Epigenetic Pharmacology. 2016, 1-25. DOI: 10.1007/978-1-4939-6631-8_69-1.Peer-Reviewed Original ResearchTranslation of genesHistone modificationsDNA methylationGenetic basisAssociated gene mutationsBiology of diseaseVariety of mechanismsTremendous discoveriesProtein expressionEpigeneticsGene mutationsDecades of researchPancreatic ductal adenocarcinomaEpigenomeMolecular agentsTranscriptionGenesMethylationBiologyMechanismMutationsDuctal adenocarcinomaPotential impactExpressionCurrent research efforts
2015
Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma
Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, Weiss MJ, Wood LD, Wolfgang CL. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Hepato Pancreato Biliary 2015, 18: 236-246. PMID: 27017163, PMCID: PMC4814593, DOI: 10.1016/j.hpb.2015.10.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Pancreatic DuctalDatabases, FactualDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Second PrimaryPancreatectomyPancreatic NeoplasmsProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPancreatic ductal adenocarcinomaNon-invasive intraductal papillary mucinous neoplasmsIntermediate-grade dysplasiaPapillary mucinous neoplasmRemnant pancreasVascular invasionMucinous neoplasmsDuctal adenocarcinomaInvasive pancreatic ductal adenocarcinomaMedian overall survivalLymph node metastasisRate of progressionSubsequent developmentIntermediate dysplasiaPancreatic resectionOverall survivalNode metastasisPerineural invasionMalignant entitiesRisk factorsPatientsDysplasiaPancreas
2010
Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas
Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, Jain A, Edil BH, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL. Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas. Annals Of Surgery 2010, 251: 470-476. PMID: 20142731, PMCID: PMC3437748, DOI: 10.1097/sla.0b013e3181cf8a19.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPancreatic ductal adenocarcinomaResection of IPMNsAdverse pathologic characteristicsInvasive pancreatic adenocarcinomaAdvanced T stageLymph node metastasisInvasive adenocarcinomaPancreatic adenocarcinomaFavorable survivalNode metastasisPathologic characteristicsT stageVascular invasionRegional lymph node metastasisFavorable biologic behaviorMicroscopic margin involvementPancreatic resection databasePositive resection marginsCox regression analysisHigh tumor gradePapillary mucinous neoplasmPoor tumor differentiationCurative intentMargin involvement
2008
Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases
Duffield AS, Jarrar P, Shum C, Ahuja N, Yeo CJ, Sokoll LJ. Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases. Clinica Chimica Acta 2008, 395: 166-169. PMID: 18505680, DOI: 10.1016/j.cca.2008.04.030.Peer-Reviewed Original ResearchConceptsHuman chorionic gonadotropinSerum human chorionic gonadotropinSerum hCG concentrationsRetroperitoneal massHCG concentrationsEpidermoid cystHCG secretionHuman chorionic gonadotropin productionCancer antigen 19Course of diseaseChorionic gonadotropin productionBenign epidermoid cystPancreatic ductal adenocarcinomaPathologic examinationAntigen 19Gonadotropin productionCyst liningMalignant neoplasmsDisease progressionDuctal adenocarcinomaPancreatic adenocarcinomaImmunohistochemical stainingChorionic gonadotropinPatientsCysts